Movair

Executive Summary

Movair (formerly International Biophysics Corporation) is a privately held medical device company headquartered in Charlotte, North Carolina, dedicated to advancing life-empowering respiratory technologies. With over 30 years of experience, the company is best known for its AffloVest, an innovative, non-invasive airway clearance system designed to help patients with chronic respiratory conditions breathe easier and improve their quality of life. By providing effective, portable solutions, Movair addresses a significant unmet need in the management of respiratory diseases such as cystic fibrosis, bronchiectasis, and COPD, enabling patients to engage in daily activities with greater freedom. The respiratory medical device market is sizable and growing, driven by rising prevalence of chronic respiratory diseases and increasing demand for home-based care. Movair's AffloVest has established a niche as a patient-friendly alternative to traditional chest physiotherapy. While the company has not disclosed recent funding rounds or valuation, its long-standing presence and commitment to innovation position it well for future growth. Potential catalysts include regulatory clearances for product line extensions, expansion into new therapeutic indications, and strategic partnerships that enhance distribution reach. With a focused product portfolio and decades of clinical credibility, Movair represents a compelling opportunity in the respiratory device space.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Next-Generation AffloVest70% success
• Q2 2026Publication of Clinical Trial Results for Use in COPD Patients60% success
• Q3 2026Strategic Distribution Partnership with Major Respiratory Device Distributor50% success